Identification of DLK1 variants in pituitary- and neuroendocrine tumors
Identification of DLK1 variants in pituitary- and neuroendocrine tumors
复制标题
DOI：
10.1016/j.bbrc.2005.12.094
复制
发表时间：
2006-02-17
影响因子：
3.1
通讯作者：
Luger, A
中科院分区：
文献类型：
--
作者：
Altenberger, T;Bilban, M;Luger, A
在常见垂体肿瘤类型的基因芯片分析中，最令人印象深刻的组织特异性表达调控基因之一是delta-like 1 (DLK1)，该基因在gh -分泌（GH-S）垂体肿瘤中强烈表达。除垂体腺瘤外，对多种内分泌肿瘤进行实时定量PCR检测，发现DLK1在正常垂体组织、GH-S-、一种泌乳素垂体腺瘤和嗜铬细胞瘤中高表达。此外，还鉴定了三个DLK1基因衍生的亚变体。第一个缺失204 bp编码表皮生长因子样结构域6和部分近膜区，被命名为Secredeltin。在另外两个剪接变异体（Brevideltin和Brevideltinin）中，由于帧移位，一个停止密码子被引入，导致204和213 aas的蛋白分别被截断。(c) 2005爱思唯尔公司版权所有。
In a gene chip analysis of common pituitary tumor types, one of the genes with the most impressive tissue-specific expression regulation was delta-like 1 (DLK1), which was strongly expressed in GH-secreting (GH-S) pituitary tumors. In addition to pituitary adenomas, various endocrine tumors were subjected to real-time-quantitative PCR revealing high expression of DLK1 in normal pituitary tissue, in GH-S-, in one prolactin-secreting pituitary adenoma and in pheochromocytomas. Additionally, three DLK1 gene-derived Subvariants were identified. The first, lacking 204 bp-coding for epidermal growth factor-like domain 6 and parts of the juxtamembrane region-was named Secredeltin. In the other two splice variants (named Brevideltin and Brevideltinin), a stop codon is introduced due to a frame-shift, leading to truncated proteins of 204 and 213 aas, respectively. (c) 2005 Elsevier Inc. All rights reserved.